{
  "description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
  "_filename": "example/Evidence-179635.json",
  "package_name": "hl7.fhir.uv.ebm",
  "statistic": [ {
    "quantity": {
      "value": 1.59
    },
    "sampleSize": {
      "numberOfParticipants": 68
    },
    "description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)",
    "statisticType": {
      "coding": [ {
        "code": "STATO:0000245",
        "system": "https://fevir.net/resources/CodeSystem/181513",
        "display": "Risk Ratio"
      } ]
    },
    "numberAffected": 30,
    "attributeEstimate": [ {
      "type": {
        "coding": [ {
          "code": "TBD:0000076",
          "system": "https://fevir.net/resources/CodeSystem/181513",
          "display": "P-value"
        } ]
      },
      "quantity": {
        "value": 0.01,
        "comparator": "<"
      },
      "description": "p < 0.01"
    } ]
  } ],
  "date": "2023-12-17T16:55:23+00:00",
  "meta": {
    "profile": [ "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow" ],
    "versionId": "4",
    "lastUpdated": "2023-12-03T09:56:07.995Z"
  },
  "publisher": "HL7 International / Clinical Decision Support",
  "name": "ComparativeParticipantFlow_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial",
  "useContext": [ {
    "code": {
      "code": "evidence-communication",
      "system": "https://fevir.net/resources/CodeSystem/179423",
      "display": "Evidence Communication"
    },
    "valueCodeableConcept": {
      "coding": [ {
        "code": "ComparativeParticipantFlow",
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "display": "ComparativeParticipantFlow"
      } ]
    }
  } ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "type": null,
  "experimental": null,
  "resourceType": "Evidence",
  "variableDefinition": [ {
    "note": [ {
      "text": "population"
    } ],
    "extension": [ {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
      "valueCode": "population"
    } ],
    "description": "Participants in the opioid detoxification trial",
    "variableRole": {
      "text": "Use extension:variableRoleCode instead.",
      "coding": [ {
        "code": "population",
        "system": "http://terminology.hl7.org/CodeSystem/variable-role",
        "display": "population"
      } ]
    }
  }, {
    "note": [ {
      "text": "exposure"
    } ],
    "extension": [ {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
      "valueCode": "exposure"
    }, {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category",
      "valueString": "false"
    } ],
    "description": "GroupAssignment: Lofexidine vs. Placebo",
    "variableRole": {
      "text": "Use extension:variableRoleCode instead.",
      "coding": [ {
        "code": "exposure",
        "system": "http://terminology.hl7.org/CodeSystem/variable-role",
        "display": "exposure"
      } ]
    }
  }, {
    "note": [ {
      "text": "outcome"
    } ],
    "observed": {
      "type": "EvidenceVariable",
      "display": "PartiicipantFlowMeasure: Dropout due to stopping intervention",
      "reference": "EvidenceVariable/179636"
    },
    "extension": [ {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
      "valueCode": "outcome"
    } ],
    "description": "Dropout due to stopping intervention",
    "variableRole": {
      "text": "Use extension:variableRoleCode instead.",
      "coding": [ {
        "code": "measuredVariable",
        "system": "http://terminology.hl7.org/CodeSystem/variable-role",
        "display": "measured variable"
      } ]
    }
  } ],
  "title": "ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
  "package_version": "1.0.0-ballot",
  "author": [ {
    "name": "Brian S. Alper"
  } ],
  "extension": [ {
    "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
    "valueCode": "cds"
  } ],
  "status": "active",
  "id": "54d8423f-393f-4482-af96-897b0c6781b8",
  "kind": null,
  "url": "https://fevir.net/resources/Evidence/179635",
  "identifier": [ {
    "type": {
      "text": "FEvIR Object Identifier",
      "coding": [ {
        "code": "ACSN",
        "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
        "display": "Accession ID"
      } ]
    },
    "value": "179635",
    "system": "https://fevir.net",
    "assigner": {
      "display": "Computable Publishing LLC"
    }
  } ],
  "version": "1.0.0-ballot",
  "relatedArtifact": [ {
    "type": "cite-as",
    "citation": "ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Evidence]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2023-11-27. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635."
  }, {
    "type": "derived-from",
    "resourceReference": {
      "type": "Citation",
      "display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal",
      "reference": "Citation/179637"
    }
  } ],
  "contact": [ {
    "name": "HL7 International / Clinical Decision Support",
    "telecom": [ {
      "value": "http://www.hl7.org/Special/committees/dss",
      "system": "url"
    } ]
  } ]
}